- Home
- CLMT vs EXEL Comparison
CLMT vs EXEL Comparison
Compare CLMT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- EXEL
- Stock Information
- Founded
- CLMT 1916
- EXEL 1994
- Country
- CLMT United States
- EXEL United States
- Employees
- CLMT N/A
- EXEL N/A
- Industry
- CLMT Oil & Gas Production
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLMT Energy
- EXEL Health Care
- Exchange
- CLMT Nasdaq
- EXEL Nasdaq
- Market Cap
- CLMT N/A
- EXEL 9.8B
- IPO Year
- CLMT 2006
- EXEL 2000
- Fundamental
- Price
- CLMT $10.48
- EXEL $37.43
- Analyst Decision
- CLMT Strong Buy
- EXEL Buy
- Analyst Count
- CLMT 5
- EXEL 18
- Target Price
- CLMT $21.80
- EXEL $37.59
- AVG Volume (30 Days)
- CLMT 1.4M
- EXEL 2.4M
- Earning Date
- CLMT 05-09-2025
- EXEL 05-02-2025
- Dividend Yield
- CLMT N/A
- EXEL N/A
- EPS Growth
- CLMT N/A
- EXEL 170.77
- EPS
- CLMT N/A
- EXEL 1.76
- Revenue
- CLMT $4,189,399,999.00
- EXEL $2,168,701,000.00
- Revenue This Year
- CLMT N/A
- EXEL $5.82
- Revenue Next Year
- CLMT $1.44
- EXEL $10.81
- P/E Ratio
- CLMT N/A
- EXEL $21.27
- Revenue Growth
- CLMT 0.20
- EXEL 18.50
- 52 Week Low
- CLMT $7.68
- EXEL $20.14
- 52 Week High
- CLMT $25.29
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- CLMT 46.82
- EXEL 57.87
- Support Level
- CLMT $8.88
- EXEL $35.34
- Resistance Level
- CLMT $10.05
- EXEL $37.67
- Average True Range (ATR)
- CLMT 1.00
- EXEL 1.32
- MACD
- CLMT 0.19
- EXEL 0.22
- Stochastic Oscillator
- CLMT 99.29
- EXEL 95.46
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.